Country and language selection

International websites


Americas / Oceania

Africa and Middle East

Asia / Pacific

KSB Group publishes preliminary results for 2019

  • Order intake, sales and EBIT in the upper half of the forecast
  • Project business drives growth
  • Net financial position improved

KSB, the Frankenthal-based manufacturer of pumps and valves, has significantly increased its order intake, sales revenue and EBIT. All the key indicators are in the upper half of the forecast made at the beginning of 2019. This is shown by the company’s provisional figures for the past financial year.

In the 2019 financial year, the volume of incoming orders booked by KSB grew by € 150 million (+6.5 %) to € 2,454 million (previous year: € 2,304 million). All three segments – Pumps, Valves and Service – were able to significantly increase both the order intake and sales revenue.

At 7.4 %, the Pumps segment achieved the largest growth in percentage terms. The increase in the Service segment was 7.3 %. The Valves segment recorded a plus of 1.8 %. All the Regions contributed to this growth. The companies in Asia accounted for the largest share – almost half – of the growth in order intake, followed by the North and South American companies at around 30 %.

Sales revenue in 2019 rose by € 137 million (+ 6.1 %) to € 2,383 million (previous year: € 2,246 million). The Valves segment recorded the highest percentage growth at 8.9 %, while the Pumps segment increased sales revenue by 6.1 % and the Service segment by 4.7 % respectively.

The net financial position also developed positively. Factoring out the first-time application of the IFRS 16 standard (new accounting treatment of leases), it was higher than in the previous year.

“Order intake was very satisfactory, especially in the first half of the year. This positive development is attributable, in particular, to the good project business. As expected, the second half of the year was more subdued due to increasing trade disputes and structural changes in some industrial sectors. All in all, we are very satisfied with the past financial year,” says CEO Dr Stephan Timmermann.